Replies to post #2397 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>How does the efficacy profile compare with that of Sustiva given the limited info available so far?<

I’m trying to dig up such information. If anyone else has it, please post.

[DewDiligence]

Re: IDX899 vs Sustiva

Slide #11 from today’s IDIX webcast depicts the mean log reduction in viral load for various HIV drugs when tested in brief monotherapy trials.

The chart shows Sustiva’s mean reduction to be 1.7 logs, less than IDX899’s mean reduction of 2.01 logs. However, the 1.7 figure for Sustiva corresponds to a lower dose (200mg/day) than the one it is approved for.

I will post the chart as soon as my web-domain problem is fixed. Regards, Dew

[DewDiligence]

>I find it surprising that the company started with a high dose [of IDX899] and is going lower, I thought it was more typical to start off with the lower doses.<

Dose escalation was done in the phase-1 multi-dose study in healthy volunteers in order to ascertain the PK and a maximum tolerated dose. This paved the way for the existing phase-1/2 study to test a dose of 800mg.

On today’s webcast, JP offered a surprising reason for testing doses of 100, 200, and 400mg per day in the next study. The reason is intriguing and hence I’m making it a quiz :-)

[DewDiligence]

The reason IDIX is trying lower doses of IDX899 is in #msg-26800695.

[DewDiligence]

IDX899 vs The Field:
#msg-26884307.